[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
March 27, 2024 14:30 ET
|
Custom Market Insights
Austin, TX, USA, March 28, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “PARP Inhibitors Market Size, Trends and Insights By Type (Olaparib, Rucaparib,...
EnGeneIC’s breakthrough Armed Nanocell Drug Conjugate (ANDC) treatment shows promising results in Pancreatic cancer patients who have run out of treatment options
November 26, 2023 23:37 ET
|
EnGeneIC
SYDNEY and NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- EnGeneIC, a pioneer in personalised cancer therapeutics, announces the publication of its clinical trial results in peer reviewed prestigious...
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors
June 05, 2023 08:00 ET
|
Immuneering Corporation
- No dose limiting toxicities observed with IMM-1-104 up to 320 mg once daily during the Phase 1a dose escalation portion of ongoing clinical study - - Phase 1b dose expansion has commenced; plan...
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
April 18, 2023 09:00 ET
|
Immuneering Corporation
Data presented at AACR Annual Meeting support IMM-1-104's potential to address a broad population of patients with RAS mutant tumorsIMM-1-104 well tolerated with no dose limiting toxicities (DLTs) or...
Global Cancer Stem Cells Market Predicted to Register a Revenue of $1,722.7 Million and Grow at a CAGR of 10.3% Over the Estimated Timeframe 2019-2026 [180-Pages] | Released by Research Dive
April 12, 2023 09:02 ET
|
Research Dive
New York, USA, April 12, 2023 (GLOBE NEWSWIRE) -- According to a report published by Research dive, the global cancer stem cells market is anticipated to garner $1,722.7 million in revenue and rise...
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
March 05, 2023 18:30 ET
|
Immuneering Corporation
Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation Phase 1/2a clinical trial with IMM-1-104 underway in patients with advanced solid...
Immuneering Announces Participation in March Investor Conferences
February 28, 2023 08:00 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
Pancreatic Cancer Treatment Market Exhibits 15.7% CAGR to Hit USD 6.85 Billion by 2029
February 20, 2023 07:04 ET
|
Fortune Business Insights
Pune, India, Feb. 20, 2023 (GLOBE NEWSWIRE) -- The global pancreatic cancer treatment market size was worth USD 2.15 billion in 2021 and is slated to rise from USD 2.48 billion in 2022 to USD 6.85...
Global Cancer Stem Cells Market Estimated to Surpass $1,722.7 Million by 2026, and Grow at a CAGR of 10.3% during the Forecast Period [180-Pages] | Confirmed by Research Dive
April 20, 2022 09:00 ET
|
Research Dive
New York, USA, April 20, 2022 (GLOBE NEWSWIRE) -- Research Dive states that the global cancer stem cells market is estimated to garner a revenue of $1,722.7 million by 2026, and rise at a CAGR of...
Qualigen Therapeutics CEO Michael Poirier Provides Letter to Shareholders
February 22, 2022 09:15 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...